Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer

Publisher： Karger

E-ISSN： 1423-0232|80|3-4|262-268

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.3-4, 2011-07, pp. : 262-268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prospective Multicenter Randomized Phase III Study of Weekly versus Standard Docetaxel plus Doxorubicin (D4) for First-Line Treatment of Metastatic Breast Cancer

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 204-210

Karger

Access to resources Recommend Favorite

Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first‐line treatment of patients with advanced breast cancer: Phase 3 randomized trial

By  

CANCER, Vol. 121, Iss. 19, 2015-10 ,pp. : 3412-3421

John Wiley & Sons Inc

Access to resources Recommend Favorite

First-Line Monochemotherapy with Mitoxantroneversus Combination with Fluorouracil, Epirubicin and Cyclophosphamide in High-Risk Metastatic Breast Cancer: A Prospective Randomized Multicenter Clinical Trial

By  

Oncology Research and Treatment, Vol. 23, Iss. 1, 2000-03 ,pp. : 54-59

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Randomized Trial of Docetaxel/Gemcitabine versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Gruppo Oncologico Italia Meridionale Study

By  

Oncology, Vol. 81, Iss. 3-4, 2011-11 ,pp. : 230-236

Karger

Access to resources Recommend Favorite

A Phase II Trial of Docetaxel and Carboplatin as First-Line Chemotherapy for Metastatic Breast Cancer: NCCTG Study N9932

By  

Oncology, Vol. 69, Iss. 2, 2005-09 ,pp. : 117-121

Karger

Access to resources Recommend Favorite